Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » FDA Issues Emergency Use Authorization for UCLA NGS-Based SARS-CoV-2 Test

FDA Issues Emergency Use Authorization for UCLA NGS-Based SARS-CoV-2 Test

Oct 07, 2020
|
staff reporter

NEW YORK – The US Food and Drug Administration on Tuesday issued Emergency Use Authorization to UCLA's SwabSeq COVID-19 Diagnostic Platform for detecting SARS-CoV-2.

The device is for the qualitative detection of the coronavirus in nasopharyngeal swabs, oropharyngeal swabs, mid-turbinate nasal swabs, and anterior nasal swabs from individuals who are suspected of having COVID-19, the disease caused by SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Issues New Guidance on SARS-CoV-2 Variants for Test Developers

  2. Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

  3. Cue Health Nabs CE Mark for Molecular Point-of-Care COVID-19 Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.